U.S., June 5 -- ClinicalTrials.gov registry received information related to the study (NCT07625891) titled 'A Phase 2 Study of D-2570 in Subjects With Non-Segmental Vitiligo' on May 28.
Brief Summary: This study tests D-2570, an investigational drug, in people with non-segmental vitiligo to check its safety and effect on skin discoloration.
Eligible participants will take D-2570, or a placebo, once daily for 24 weeks in a double-blind setting. Most will then continue into a 24-week extension phase, where those on 27 mg or placebo will switch to one of the lower doses.
All participants will have a 4-week safety follow-up after treatment ends, with regular check-ups and blood tests throughout the study.
Study Start Date: May 30
Study Typ...